Global Ultrasound Leader Chison Medical Partners with AstraZeneca and BD to Empower County-Level Healthcare in China

Source: Shike Toutiao

January 23, Ultrasound LeaderCHISONWith Top Pharmaceutical CompaniesAstraZeneca, signed an MOU with global giant BD to establish a Training Academy for Appropriate Technologies in China’s County-Level Healthcare, leveraging the respective strengths of the three parties to improve medical service delivery at the county level, implement the tiered diagnosis and treatment system, achieve integrated precision diagnosis and treatment, and advance the Healthy China initiative.

For a long time, CHISON has closely followed the global trend of ultrasound-based medical diagnostics, consistently pursuing innovation and consciously shouldering the mission of “improving healthcare and creating value through technology.” Committed to addressing clinical pain points and deeply cultivating specialized fields, CHISON has established significant differentiated competitive advantages in specialization, portability and miniaturization, and intelligence, thereby assuming industry responsibility for leading global ultrasound development trends. In active response to national policy initiatives, CHISON has joined forces with AstraZeneca and BD, leveraging the combined strengths of the three parties to actively promote the downward distribution of high-quality medical resources. This collaboration helps drive overall improvements in county-level healthcare services and advances the high-quality development of health initiatives in the new era.

Focus on Primary Care Diagnostic and Treatment Capabilities: Co-building a Smart and Beneficial Medical Consortium

During the 13th Five-Year Plan period, strategic decisions and deployments were made to implement the Healthy China initiative. Within the broader framework of the “Healthy China 2030” planning outline, national and local governments have introduced a series of policies to promote early screening and diagnosis of high-incidence diseases. Deepening comprehensive healthcare reforms at the county level is a crucial component of implementing the Healthy China strategy and achieving rural revitalization, while also creating significant market opportunities.

Industry insiders point out that, driven by the tiered diagnosis and treatment system, as well as the dual forces of government administrative intervention and patient demand, the need to enhance the comprehensive capabilities of county-level hospitals is relatively rigid, presenting significant market opportunities. In the future, the grassroots healthcare market will experience rapid growth, with broad development prospects.

Faced with the vast and populous grassroots level of county-level regions, CHISON has started by popularizing appropriate technologies to promote high-quality medical resources into townships and counties. This move not only recognizes the huge opportunities within the grassroots market but also holds significant importance for improving the treatment capabilities of county-level hospitals. Meanwhile, CHISON’s future development is expected to benefit from the explosive growth dividends of the grassroots healthcare market.

From the perspective of specific collaboration, AstraZeneca, as an innovation-driven global biopharmaceutical company, adheres to the core value of "patient-centricity" and is committed to improving patients' quality of life through early screening and diagnosis of diseases. CHISON partnered with AstraZeneca in 2020 to establish an Ultrasound Academy, leveraging the advantages of ultrasound—non-ionizing, non-invasive, and painless—to help patients detect diseases earlier and receive more precise diagnosis and treatment. Addressing the pain points and needs of county-level healthcare, AstraZeneca’s County Team proposed the Smart Healthcare Consortium Project, aiming to drive multi-dimensional model innovation together with partners and promote the decentralization of high-quality medical resources. This strategic signing between CHISON and AstraZeneca’s County Team marks the commencement of comprehensive cooperation between the two parties across broader fields.

BD is one of the top five medical device companies globally. In 2018, CHISON signed a strategic cooperation agreement with BD to collaborate in the field of ultrasound imaging. This time, BD, together with AstraZeneca and CHISON, will further cooperate to establish an academy, providing continuous and systematic project support for the county-level market, pooling professional resources to deliver specialized services, and enhancing the well-being of residents in county-level areas.

Mo Ruoli, General Manager of CHISON, stated that the company, leveraging its foundation in ultrasound technology, has engaged in extensive innovative collaborations with AstraZeneca in areas such as breast health, urology, and cardiovascular care. In partnership with BD, CHISON has co-developed specialized ultrasound systems for peripherally inserted central catheter (PICC) placement, enhancing the capability of nursing professionals in China to provide precise catheterization services for patients undergoing tumor chemotherapy. The strategic cooperation among these three companies is itself an innovation. By capitalizing on their respective technological strengths and clinical expertise, CHISON will empower the improvement of diagnostic and treatment capabilities at the county level, thereby benefiting hundreds of millions of residents in county-level regions.

Continuous Innovation Leads the Development Trend of Ultrasound, Jointly Building a Healthy China

As a strategic partner of two top-tier international enterprises, CHISON has dedicated itself to ultrasound technology for 25 years. Guided by its corporate vision of “Making Everyone Healthier” and adhering to its core value of “Improving Healthcare and Creating Value through Technological Innovation,” CHISON has successively undertaken major national research projects during the 12th and 13th Five-Year Plan periods. The company holds over 400 global patents and copyrights, with its products and services reaching users in more than 100 countries worldwide, establishing itself as a leader in shaping global ultrasound development trends. Looking ahead, the company aims to become the leading player in specialized ultrasound and rank among the top two Chinese ultrasound brands.

As a domestic enterprise, CHISON possesses a natural advantage in its “understanding” of the clinical pain points in China’s primary healthcare sector. The development of leading technologies—such as 5G-enabled remote ultrasound-guided surgery, SonoAI artificial intelligence for ultrasound, smart medical IoT connectivity, and IPX7-rated immersible disinfection—has effectively addressed these clinical challenges. These innovations enable residents in county-level areas to receive high-precision diagnostics at local hospitals without the need for long-distance travel; allow county-level healthcare professionals to continuously enhance their specialized skills without leaving their posts for off-site training; and assist hospital administrators in county-level institutions to better serve patients while minimizing the risk of nosocomial infections, particularly in the context of the pandemic.

Following the signing of this agreement, CHISON will strengthen training on appropriate technologies for county-level healthcare, enhance the disease treatment capabilities of local hospitals, and promote opportunistic screening for common diseases. This initiative will not only benefit the health of the broader grassroots population but also further bolster brand influence, thereby increasing public awareness of the advantages of ultrasound medical diagnosis.

At the academy’s inauguration ceremony and training conference, clinicians from CHISON Medical and the People’s Hospital delivered lectures on the physical foundations, principles, operation, and practical experience of ultrasound. They also conducted live demonstrations of prostate biopsy and initial dialysis procedures using the high-end notebook color Doppler ultrasound system SonoBook 9. This multifaceted teaching approach, integrating theory with practice, greatly benefited both online and offline participants, who expressed their commitment to applying what they had learned to enhance county-level healthcare. By leveraging the combined strengths of all three parties, the initiative aims to contribute to the “Healthy China 2030” strategy.

In summary, as a leader in global ultrasound development trends, CHISON aligns closely with China’s national strategies and actively collaborates with industry giants to deepen the implementation of the Healthy China Initiative. This contributes to comprehensively enhancing primary healthcare infrastructure and promotes the building of a community of common health for mankind. Amidst new opportunities for development, driven by policy support and dividends from the growth of the primary care market, CHISON is poised to achieve leapfrog growth in both performance and business operations. This will help accelerate the realization of its strategic goals: becoming the leading specialist in ultrasound and securing a position among the top two Chinese ultrasound brands.